secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001558370-23-008683
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kala Pharma Q1 net loss $14.5M; KPI-012 CHASE Phase 2b enrolling with topline data Q1 2024
--------------------------------------------------------------------------------

- Q1 2023 net loss $14.5M ($6.99/share) vs $32.9M ($22.18/share) in Q1 2022; no product revenue post-Alcon sale.
- Cash and equivalents $63.6M at March 31, 2023; plus $15M CIRM grant awarded April 2023 extends runway into Q1 2025.
- KPI-012 for PCED received FDA Fast Track designation; CHASE Phase 2b primary enrollment ongoing; topline data targeted Q1 2024.
- Appointed Dr. Francis Mah as Chief Medical Advisor in March 2023 to support clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023008683/0001558370-23-008683-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023008683/kala-20230509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-008683

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer